Abbreviations: (CV) coefficient of variation, (MI) monomeric insulin, (NLS) nonlinear least squares, (NPH) neutral protamine Hagedorn, (PK) pharmacokinetic, (RI) regular insulin, (SC) subcutaneous, (SSE) sum squared error Keywords: blood glucose, compartmental models, decision support, diabetes, hyperglycemia, insulin, simulation, subcutaneous injection The goal of this study was to develop a unified physiological subcutaneous (SC) insulin absorption model for computer simulation in a clinical diabetes decision support role. The model must model the plasma insulin appearance of a wide range of current insulins, especially monomer insulin and insulin glargine, utilizing common chemical states and transport rates, where appropriate.
Introduction
For more than 80 years, administration of insulin via the subcutaneous (SC) route into the peripheral circulation has been the most widely used therapy in ambulatory diabetes. Since Binder, 1 the absorption kinetics of subcutaneously injected insulin has emerged as a mature research field. [2] [3] [4] Insulin absorption kinetics are complex and can be influenced in many complex ways. Insulin-independent factors include SC blood flow (which can be influenced by temperature, 2,5 exercise, 6, 7 and even smoking 8, 9 ), depth of injection, 10, 11 and site of injection. 4 There are also insulin-dependent factors, which include the species of insulin 12 and the concentration and volume of injected insulin. 1, 4, 10, 13 As a result, SC insulin pharmacokinetics (PK) are variable enough to offer significant practical difficulties in providing consistent therapy for diabetes. Most studies report interindividual variation in key pharmacokinetic summary measures from 15 14 to 107%, 4 depending on insulin type.
Some diabetes decision support and control methods [15] [16] [17] [18] rely on SC absorption models to deterministically predict plasma insulin appearance from SC injection, thus tracking on-board insulin from multiple doses over extended periods. Some would argue the clinical value to general diabetes management of such models given the inherent and significant intra-and interpatient variability in absorption.
14, [19] [20] [21] [22] [23] Nevertheless, given the often limited data available for glycemic control in diabetes, 24, 25 the qualitative estimation of the plasma insulin time course is not only useful but necessary for efficient dosing and reduced risk of hypoglycemia. Deterministic models of absorption can also form the basis of stochastic methods, as hinted at by Andreassen and colleagues 18 with significant potential. These models have also proven useful for glycemic control simulation 15, 18, 26 and diabetes education.
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Previous work in insulin PK modeling is voluminous. Kobayashi and associates 28 experimented with singleand dual-compartment models for regular insulin (RI) absorption. As most current regular insulin is regular human insulin, the term regular insulin in this study is taken to mean regular human insulin. Later, Kraegen et al. 29, 30 developed a three-compartment model, which was refined with a minimal approach by Puckett et al., 31 modeling the long-acting ultralente insulin as an unlikely continuous flow in addition to RI. As the use of monomeric insulin (MI) types matured clinically, more models concentrated on its absorption kinetics. In this study and elsewhere, the term "monomeric insulin" is a convenient misnomer used for rapid-acting insulin analogues whose hexamers dissociate very rapidly into dimers/monomers in subcutaneous tissue, resulting in a monoexponential decay curve. 32 With a similar threecompartment model, Shimoda et al. 17 modeled both RI and MI absorption. More recently, Wilinska et al. 33 demonstrated a four-compartment model of MI absorption with fast/slow absorption channels and local insulin degradation.
All these models apply to prandial insulin only, which is limiting, as basal-acting insulin is required in ~90% of all insulin-dependent diabetics not on insulin pump therapy (calculated based on estimated insulin pump use 34 13 describes the absorption kinetics with coupled partial differential equations of detailed physicochemical properties of insulin. While accounting for dose, volume, and concentration dependency, solving the nonlinear-coupled differential equations it employs is computationally burdensome and only RI is modeled. This model was simplified by Trajanoski et al. 37 and subsequently extended by Tarin et al. 38 to insulin glargine, a long-acting basal insulin analogue, and is currently the only model for this newer insulin. While these noncompartmental models are more physiological than the compartmental models, the associated computational cost can be prohibitive, especially if the intended or potential end use is a realtime diabetes decision support system.
In summary, the complex, noncompartmental models better capture some published insulin absorption kinetics, while the computationally minimal compartmental models better suit simulation in a real-time diabetes decision support system. The more complicated kinetics of RI have not been modeled compartmentally nor have insulin glargine or even older intermediate and longacting insulin types such as lente and ultralente. Most existing models also describe only one insulin type or a limited number with no commonality. 17 Critical reviews of some of these models are available from Nucci and Cobelli. 39 Compartmental modeling methods are also well reviewed in Carson and Cobelli. 40 This article developed a physiological compartment model for a wide range of insulin types. Specifically, fast-and short-acting prandial insulins (MI and RI) and intermediate-and long-acting basal insulins (NPH, lente, ultralente, and insulin glargine) are modeled. The main principle was to more accurately capture the main dynamics of the absorption kinetics with a compartmental model using first-order kinetics. The secondary goal was to provide a computationally minimal, yet consistent, physiologically unified framework for all insulin types. The model also accounts for volume and concentration dependency on SC absorption of human insulins. The intended end use is as a simulation model for a real-time decision support system.
Methods
A diagram of the structure of the SC insulin absorption kinetic model is shown in Figure 1 . The model equations are then listed, followed by a description of the individual sections of the model for each insulin type. After this description, a summary of the model is presented. 
Regular Insulin Submodel Structure
The RI model [Equations 1 and 2] is based on insulin physicochemical properties. 13 For soluble human insulins, it is generally accepted that the dynamic equilibrium of the hexameric, dimeric, and bound states characterizes absorption kinetics. 32, [41] [42] [43] The equilibrium is concentration dependent and is destabilized by dilution and diffusion in the SC depot. 13, 44 Qualitatively, the monomeric state has the highest absorption rate into plasma 32 and becomes increasingly stable toward the end of the absorption process when insulin concentration at the site decreases.
For simplicity, the dimeric and monomeric states are lumped in x dm (t) [see Equation 2]. Both states have higher relative absorption rates into plasma than the hexameric state, although the dimer is absorbed discernibly slower than the monomer. 32 There is no provision for a reversible, bound state. 13 However, for many common concentrations of insulin preparation, insulin binding has been shown to be negligible. 37 Reversible binding also becomes apparent only at low doses and concentrations. 13 This result implies that the effect of insulin binding is relatively small, especially when large prandial injections are administered, and might be ignored for decision support. 
Insulin Glargine Submodel Structure
The insulin glargine model structure has several key differences to the NPH, lente, and ultralente models [Equations 7 and 8]. The model structure consists of a precipitate compartment, p gla (t) [Equation 8 ], similar in purpose to the crystalline state compartment for NPH and zinc-based insulins. Like the formation of crystals, the formation of an amorphous microprecipitate in neutral SC tissue is the primary protraction mechanism of insulin glargine, which has an acidic isoelectric point. 46 An empirical approximation is used to model the maximum dissolution rate, r dis,max , of the precipitate [Equations 27 and 28] into a hexameric form unique to glargine, x h,gla (t).
where H(t -t i ) is the Heaviside function defined as H(t -t i ) = 0 when t is less than t i , and H(t -t i ) = 1 when t is greater than or equal to t i . Thus, r dis,max is a function of dose size for doses >30 units and is a constant 15 mU/min for doses <30 units. This function has been selected based on the following model identification of the model parameters in this research. The glargine insulin hexamer is also strengthened to reduce dissociation, [46] [47] [48] 
Monomeric Insulin Submodel Structure
The MI model structure follows from the RI model structure in that the MI dose is assumed to be injected is physiological, but highly simplified compared to nonlinear noncompartmental approaches.
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First-order transport rates are used except where in vivo knowledge is unpublished or unknown. In this case, empirical assumptions were made as in the case of the dose response of insulin glargine [Equations 27 and 28]. In this particular case, the empirical approximation is based on observations during model identification, as presented in this study.
While the absorption processes, i.e., dissolution, dissociation, and diffusion, are two way, only the net flow to plasma is modeled. This approach is another acknowledged simplification from other more complex models. It is similar to the recent compartment model of Clausen and colleagues 52 for a biphasic protamineretarded MI-MI preparation. This particular model also has a similar crystalline state compartment and models only net flows, but with no hexameric state due to the use of MI.
Model Parameter Identification
Certain model parameters are fixed to values in the literature and used as patient-independent population values ( Table 1 ). All remaining parameters for all insulin types are patient specific and identified with nonlinear least squares (NLS) and unconstrained nonlinear optimisation methods. Data utilized are taken from 37 sets of plasma insulin time-course absorption curves ( Table 2) .
Data were collected via a literature review of relevant insulin PK studies searched in the MEDLINE and Science Citation Index Expanded (SCI-EXPANDED) databases. Only studies using direct measurement methods were considered 53 with data generally in the form of mean plasma insulin time-course measurements. These studies differ widely in cohort studied, methods, and protocol. However, data suffice for this study where the goal was to develop a mean PK simulation model for a diabetes decision support system. Rather than limiting the parameter identification to a specific cohort, experimental method, and/or protocol, a parameter fit across a broad range of studies is felt to be likelier to result in an averaged PK response suitable for clinical use over the similarly wide population encountered in the general diabetes control problem.
Several major factors may affect data used for parameter identification. First, insulin antibodies may not be quantified and/or cannot be presumed negligible. This problem is an issue more with IDDM study cohorts with an extended history of diabetes that have been or are being treated using older, highly immunogenic insulin types, e.g., porcine insulin. If the cohort is not naive to the specific insulin used, insulin antibodies can significantly affect the plasma insulin concentration measurement.
Insulin antibodies generally affect plasma insulin appearance proportionately, leading to inaccurate insulin distribution volume assumptions. 28 However, in a modelbased diabetes decision support system where effective insulin sensitivity is optimized in real time, 51 ,54 a tradeoff between effective insulin sensitivity and insulin distribution volume can occur. 55, 56 In this case, the shape of the plasma insulin curve is more critical within reasonable bounds than its exact magnitude. 55 Second, endogenous insulin production may not be corrected or be presumed negligible. This determination is typically performed using C-peptide measurements for noninsulin-dependent diabetes mellitus or normal study cohorts. In most cases, however, administered doses are sufficient to suppress endogenous insulin production, and its effect may largely be disregarded when using a large number of studies for an average identification.
Finally, in the case of insulin analogues, especially insulin glargine, or animal-based insulins, insufficient cross-reactivity with a nonspecific insulin assay may result in underestimated plasma insulin concentrations. With respect to these concerns, all studies are specifically identified in Table 2 where insulin antibodies and endogenous insulin production are accounted for. Similarly, if cross-reactivity with the insulin assay of the study insulin is sufficient. If concentration of the insulin preparation is not quoted, a typical concentration of 100 U/ml is assumed. If the insulin dose is quoted in units per kilogram, a body weight of 80 kg is assumed if no other information is provided. All of these assumptions are indicated where made and illustrate the lack of full data reporting that can often occur.
The model is built essentially by extensions from the MI model structure (Figure 1) , which is identical to the one by Shimoda et al. 17 and similar to the ones by Kraegen and Chisholm 29 and Puckett and Lightfoot. 31 Equivalent parameter values from Shimoda and colleagues 17 were thus able to be used as starting points for NLS optimization of k 2 and k 3 to MI studies data ( Table 3) . With fixed population values of k 2 and k 3 identified from MI data, a two-stage NLS optimization is used to optimize k 1 , k 2 , and k 3 using data from RI studies ( Table 4 ). Note that the overall fitted k 2 and k 3 values for RI data ( Table 4) are very close to the fitted k 2 and k 3 to MI data (Table 3) and that all fitted parameters display a low coefficient of variation (CV) as summarized in Table 9 . Hence, the k 2 and k 3 parameters are consistent in describing these common physiological states during the SC insulin absorption process even among different insulin types.
Referring to Figure 1 , two parameters each must be identified for the NPH (k crys,NPH and α len ) and lente insulin (k crys,len and α NPH ) data set, where fixed population k 1 , k 2 , and k 3 values from RI and MI data parameter identification are used. Likewise, three parameters must each be fitted for the ultralente (k crys,ulen , k 1,ulen , and α ulen ) and insulin glargine (k prep,gla , k 1,gla , and α gla ) data sets using the same fixed k 1 , k 2 , and k 3 population values.
Because of the larger number of data sets, parameters for the NPH, lente, ultralente, and insulin glargine submodels are fitted via unconstrained nonlinear optimization using a simplex search method for multiple variables, which is a quicker method. The objective function is the plasma insulin concentration sum squared error (SSE), defined in Equation 31 for the jth data set. As only mean insulin time-course data are used in this study, the variability of the mean value is neglected. Depending on the number of measurements in the calculation of the mean, the sum of the percentage measurement error would result in a wide error band around each mean value, which is of little value for model fit validation.
where N j is the number of plasma insulin data points in the jth data set, is the ith plasma insulin concentration data point in the jth data set, and is the modeled plasma insulin concentration for the jth data set at t j,i , the time at the ith plasma insulin concentration data point. There are 37 data sets in total for all insulin types (4 MI, 12 RI, 10 NPH insulin, 1 lente insulin, 4 ultralente insulin, and 6 insulin glargine).
Results for the NPH, lente, ultralente, and insulin glargine parameter identifications are shown in Tables 5-8 . Note that even with fixed population values for k 1 , k 2 , and k 3 , the CV of all fitted NPH, lente, ultralente, and insulin glargine model parameters was <100%. Specifically, a median CV of 57% and a 95th percentile of 3.6-69.1% were achieved (results not shown). Referring to Table 9 , the median CV was 51.3% (95th percentile of 3.6-60.6%) across all parameters and insulin submodels. This precision of fitted parameters is adequate given the data, and the parameters can be considered a posteriori identifiable following the definition of Wilinska and colleagues. 33 
Model Fit and Prediction Errors
In Table 10 , model fit error (both absolute and absolute percentage errors) and model prediction errors using population parameters (both absolute and absolute percentage errors) are shown. Across all insulin types, median absolute model fit errors range from 0.62 to 3.20 mU/liter and median absolute percentage model fit errors range from 10.96% for glargine to 21.42% for lente, of which there was only one data set. This figure is hence unaffected by the averaging effect of multiple studies and may not be accurate. To calculate the model prediction errors, the plasma insulin concentration is generated using the model and the population parameters identified. As expected, the more stable insulin analogues, e.g., MI and glargine, have much lower model prediction errors (13.30 and 10.96%, respectively), whereas the more variable insulins, e.g., RI (18.35%) and NPH (16.25%), have considerably higher prediction errors. The more stable insulin analogues are hence better predicted using fixed population parameter values than less stable insulin types.
Conclusions
A simple, physiological compartmental model has been developed for computer simulation of SC injected insulin PKs for a diabetes decision support system. Most clinically current insulin types, including MI, RI, NPH, and insulin glargine, are modeled. The model accounts for concentration dependency of SC RI injection and models the dose dependency of insulin glargine absorption. In total, 13 patient-specific model parameters were fitted to 37 sets of plasma insulin mean time-course data over all insulin types from reported clinical studies. The remaining model parameters were assumed patientindependent constants and a priori identified from the literature. All fitted parameters have a coefficient of variation <100% (median 57%, 95th percentile 3.6-60.6%) and can be considered a posteriori identifiable. Hence, a model has been created based on known SC absorption kinetics and identified on a broad range of clinically reported studies. The precision in identified parameters is acceptable and the main clinically current insulin types have been modeled. Future validation of the model fit using clinical data is required.
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